SynthesisEuropean journal of neurology2025
Anti-IgLON5 Disease: A Systematic Review and Meta-Analysis.
Synthesis in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-IgLON5 Disease: A Systematic Review and Meta-Analysis.European journal of neurology · 2025Pooled it
- Current and Future Biomarkers in the Diagnosis of Autoimmune Encephalitis: A Review of Biomarker Detection Techniques and Their Performance.Medicina (Kaunas, Lithuania) · 2026Review
- Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report.Frontiers in immunology · 2026Article
- Facio-Brachial Dystonic Seizures as an Atypical Presentation of Anti-IgLON5 Disease.Journal of central nervous system disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-IgLON5 disease is now considered a complex and heterogeneous neurological disorder with sleep, movement, and neuroimmunological as well as neurodegenerative aspects. The aim of this systematic review and meta-analysis was to entail the whole clinical spectrum as well as laboratory characteristics, therapeutic interventions and reported outcomes of anti-IgLON5 disease.
methodsThe electronic databases PubMed/MEDLINE, Web of Science and Semantic Scholar were searched for case reports and case series on anti-IgLON5 disease published until July 31, 2024. For inclusion, studies had to report on patients with a positive IgLON5 antibody titer in serum or CSF and be published in English in a peer-reviewed journal. For meta-analyses, only case series with N ≥ 10 patients were considered. The risk of bias was assessed with the JBI critical appraisal tool.
resultsA total of 285 patients (N case series/case reports = 85) with anti-IgLON5 disease were included in this systematic review. Sleep abnormalities (N = 218; 76.5%), bulbar dysfunction (N = 175; 61.4%) and movement disorders (N = 160; 56.1%) were most frequently reported. The prevalence of IgLON5 antibodies in the serum was 99.6% (N reported = 276).
conclusionBased on our results, anti-IgLON5 disease should be considered in patients presenting with sleep disorders and additional neurological symptoms that might resemble other diseases but do not fulfill the respective diagnostic criteria. Testing for antibodies in serum has a high sensitivity in this disorder. A limitation of this study is that it was not preregistered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.